Replies to post #320637 on Avid Bioservices Inc (CDMO)

[biopharm]

Sponsors

Memorial Sloan Kettering gratefully acknowledges the following organizations for providing educational grants or financial support for this live activity:

ACEA Biosciences, Inc.
Adaptive Biotechnologies
Eureka Therapeutics, Inc.
Juno Therapeutics
Kite, a Gilead Company
Novartis

...only one on that list with big $$$ to make a big deal with Peregrine

[north40000]

From your 2nd link to MSKCC:

"Preliminary results from a phase I clinical trial at MSK have shown the BCMA-targeted CAR T therapy to be safe at low levels. MSK researchers are slowly raising the dosage to find the ideal amount and there has already been one striking outcome. PET scans had initially showed myeloma all over a female patient’s body, but four weeks after receiving CAR T cells, the tumors had shrunk dramatically or vanished. She remains in a complete remission more than three months after treatment. (The woman had to discontinue from the clinical trial for unrelated reasons.)

“That’s an exciting result that shows this therapy can be effective,” Dr. Smith says....."

Not melanoma yet.

I wonder what was said in the 2-day conference in NYC at the Zuckerberg center in November? Any papers available?